Seeking Alpha

If you missed the incredible run up in share price that Santarus (SNTS) has achieved over the past 18 months, now may be the perfect time to ride the next wave up. Santarus has been one of the strongest stocks in the biotech sector this year with a YTD increase over 350%. The dramatic price increase has been driven by several positive catalysts as described below. Despite this stellar performance, a series of events has contributed to a recent sell off, opening the door for investors to buy shares at a deeply discounted price. In this article I will explain why I believe near term indications with both commercial and pipeline products could alone, be worth significantly...

Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: